Management of early stage chronic myeloid leukemia: State-of-the-art approach and future perspectives

Federica Galaverna, Chiara Ghiggi, Fabio Guolo, Germana Beltrami, Clara Dellepiane, Livia Giannoni, Andrea Carella, Angelo M. Carella

Research output: Contribution to journalArticle

Abstract

Tyrosin Kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-tonormal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15% of all patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for treating, and possibly curing, CML in the upcoming years.

Original languageEnglish
Pages (from-to)749-754
Number of pages6
JournalCurrent Cancer Drug Targets
Volume13
Issue number7
Publication statusPublished - 2013

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myeloid Progenitor Cells
Life Expectancy
Drug-Related Side Effects and Adverse Reactions
Cell Biology
Phosphotransferases
Survival Rate
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chronic myeloid leukemia
  • New therapeutic strategies
  • Stem cell biology
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Galaverna, F., Ghiggi, C., Guolo, F., Beltrami, G., Dellepiane, C., Giannoni, L., ... Carella, A. M. (2013). Management of early stage chronic myeloid leukemia: State-of-the-art approach and future perspectives. Current Cancer Drug Targets, 13(7), 749-754.

Management of early stage chronic myeloid leukemia : State-of-the-art approach and future perspectives. / Galaverna, Federica; Ghiggi, Chiara; Guolo, Fabio; Beltrami, Germana; Dellepiane, Clara; Giannoni, Livia; Carella, Andrea; Carella, Angelo M.

In: Current Cancer Drug Targets, Vol. 13, No. 7, 2013, p. 749-754.

Research output: Contribution to journalArticle

Galaverna, F, Ghiggi, C, Guolo, F, Beltrami, G, Dellepiane, C, Giannoni, L, Carella, A & Carella, AM 2013, 'Management of early stage chronic myeloid leukemia: State-of-the-art approach and future perspectives', Current Cancer Drug Targets, vol. 13, no. 7, pp. 749-754.
Galaverna F, Ghiggi C, Guolo F, Beltrami G, Dellepiane C, Giannoni L et al. Management of early stage chronic myeloid leukemia: State-of-the-art approach and future perspectives. Current Cancer Drug Targets. 2013;13(7):749-754.
Galaverna, Federica ; Ghiggi, Chiara ; Guolo, Fabio ; Beltrami, Germana ; Dellepiane, Clara ; Giannoni, Livia ; Carella, Andrea ; Carella, Angelo M. / Management of early stage chronic myeloid leukemia : State-of-the-art approach and future perspectives. In: Current Cancer Drug Targets. 2013 ; Vol. 13, No. 7. pp. 749-754.
@article{e6f28fbeb0734f6794ed359050695761,
title = "Management of early stage chronic myeloid leukemia: State-of-the-art approach and future perspectives",
abstract = "Tyrosin Kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-tonormal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35{\%} of the patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15{\%} of all patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for treating, and possibly curing, CML in the upcoming years.",
keywords = "Chronic myeloid leukemia, New therapeutic strategies, Stem cell biology, Tyrosine kinase inhibitors",
author = "Federica Galaverna and Chiara Ghiggi and Fabio Guolo and Germana Beltrami and Clara Dellepiane and Livia Giannoni and Andrea Carella and Carella, {Angelo M.}",
year = "2013",
language = "English",
volume = "13",
pages = "749--754",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Management of early stage chronic myeloid leukemia

T2 - State-of-the-art approach and future perspectives

AU - Galaverna, Federica

AU - Ghiggi, Chiara

AU - Guolo, Fabio

AU - Beltrami, Germana

AU - Dellepiane, Clara

AU - Giannoni, Livia

AU - Carella, Andrea

AU - Carella, Angelo M.

PY - 2013

Y1 - 2013

N2 - Tyrosin Kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-tonormal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15% of all patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for treating, and possibly curing, CML in the upcoming years.

AB - Tyrosin Kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-tonormal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15% of all patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for treating, and possibly curing, CML in the upcoming years.

KW - Chronic myeloid leukemia

KW - New therapeutic strategies

KW - Stem cell biology

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84888051589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888051589&partnerID=8YFLogxK

M3 - Article

C2 - 23952099

AN - SCOPUS:84888051589

VL - 13

SP - 749

EP - 754

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 7

ER -